The invention relates to the technical field of heart electrophysiological information analysis, in particular to a data analysissystem and method based on three-dimensional heart modeling, and the method comprises the steps: obtaining a heart three-dimensional medical image, reconstructing a heart muscle grid, constructing a public heart coordinate, and dividing the surface of an endocardium into a plurality of endocardium partitions; fusing catheter mapping points and local potential waveforms on the geometric model, establishing a three-dimensional electrophysiological propagation model consistent with individual anatomy, and forming heart digital twinning; a structural network and a propagation network are constructed based on endocardium partition, an excitation propagation path and a turn-back risk are analyzed, and influences of different targets on the turn-back risk are compared through virtual ablationsimulation, so that a quantitative basis is provided for myocardial ablation target selection and intervention strategy formulation.
Circuitless heart rhythm determination can include capturing a video clip of one or more image frames of a target organ through an ultrasound imaging device and submitting the frames to a classifier that has been trained with an annotated set of images, each of a corresponding heart muscle captured at a specified phase of a heart rhythm with a ground truth indication of the specified phase of the heart rhythm drawn from a separately recorded cycle graph of an electrical signal measured over time for the corresponding heart muscle. In response to the submission, a classification can be received of different portions of the submitted frames according to corresponding phases of the heart rhythm. Finally, a contemporaneous phase of the heart rhythm can be determined in the device without sensing electrical signals by way of a closed-loop sensor circuit affixed proximately to the target heart muscle.
The invention relates to an application of D-ribose in a cumulative exercise fatigue subject, which is beneficial to improving and / or protecting the myocardial function of the subject, improving the myocardial hypoxia tolerance of the subject, improving and / or protecting the skeletal muscle function of the subject, reducing the inflammation occurrence risk of the subject, and improving the exercise performance ability and exercise tolerance of the subject. And / or accelerating exercise fatigue recovery.
A method for manufacturing a multilayer engineered heart muscle that includes (i) providing a liquid reconstitution mixture in a mould and (ii) culturing the mixture. The method includes a sequential addition of one or more further liquid reconstitution mixtures to obtain a multilayer engineered heart muscle. The muscle ideally has the form of a patch, a pouch, or a cylinder. Furthermore, a multilayer engineered heart muscle having collagen, cardiac myocytes and non-myocytes originating from at least 2 layers is disclosed. The multilayer engineered heart muscle forms the basis for several in vitro and in vivo applications such as the production of a multilayer engineered heart muscle for use in a patient, for example for use in heart repair.
The present invention relates to an implantable device for improving the pump function of the heart of a human patient by applying an external force on the heart muscle. The implantable device comprises at least one implantable pump device comprising: A fluid, A first reservoir having a first volume and at least one movable wall portion, for varying said first volume, and A second reservoir being in fluid connection with said first reservoir. Wherein said implantable pump device is adapted to allow free flow of fluid between said first reservoir and said second reservoir, and wherein said first reservoir, said second reservoir and said fluid connection forms a fully implantable closed pump device, and wherein said fully implantable closed pump device is adapted to transfer force from said first reservoir to said second reservoir.
Devices and systems as described herein is configured to sense a signal, such as a signal from an individual. In some embodiments, a signal is a magnetic field. In some embodiments, a source of a signal is an individual's organ, such as a heart muscle. A device or system, in some embodiments, comprises one or more sensors, such as an array of sensors configured to sense the signal. A device or system, in some embodiments, comprises a shield or portion thereof to reduce noise and enhance signal collection.
Various methods and systems for medical imaging systems are provided. In one embodiment, a method includes generating a cardiac ultrasound image from ultrasoundimaging data of a heart, generating a spatiotemporal map of electrical impulses in the heart based on contractions and elongations of heart muscle depicted in the cardiac ultrasound image, and outputting the spatiotemporal map of electrical impulses in the heart to a display device. In this way, the spatiotemporal map of electrical impulses in the heart can visually indicate electrical conduction pathways through the heart.
The present invention relates to a myocardial spectrometer probe, comprising: at least two separate light guides (120A, 120B), insertable in a tissue, wherein a first light guide (120A, 120B) is arranged to deliver light and a second light guide (120A, 120B) is arranged to collect light, and wherein the first light guide (120A, 120B) and the second light guide (120A, 120B) are arranged distinct to each other.
The invention provides an application of a rhizoma polygonati aqueous extract in preparation of a product for relieving cardiac myocardial injury caused by semeglutide, provides a new application of the rhizoma polygonati aqueous extract, and can effectively relieve the problem of myocardial musclearea reduction caused by semeglutide treatment. When the rhizoma polygonati aqueous extract is used together with the simeglutide, the rhizoma polygonati aqueous extract has the characteristics of not influencing the weight-losing effect and the fat-reducing effect, also has protection and repair effects on cardiac muscle, has dual effects of keeping the fat-reducing effect and relieving myocardial injury, and provides an effective auxiliary scheme for safe use of the simeglutide.
The invention discloses a myocardial activity concentration determination method and a related device, and relates to the technical field of nuclear medicinecardiac imaging, and the method comprises the following steps: converting acquired cardiac muscle body data under a human body coordinate system into cardiac muscle body data under a mandrel coordinate system; aiming at the cardiac muscle body data under the mandrel coordinate system, dividing the cardiac muscle body data under the mandrel coordinate system into ellipsoidal heart muscle body data and cylindrical heart muscle body data along the cardiac muscle short axis direction of the mandrel coordinate system; and respectively performing fan-shaped sampling and parallel sampling on the ellipsoid heart body data and the cylindrical heart body data to obtain multi-layer ellipsoid cardiac muscle short axis data and multi-layer cylindrical cardiac muscle short axis data. Carrying out data sampling on each layer of ellipsoid cardiac muscle short axis data and each layer of cylindrical cardiac muscle short axis data to obtain the cardiac muscle activity concentration of the left ventricle, the cardiac muscle activity concentration of the left atrium and the cardiac muscle activity concentration of the basal part; and more accurate myocardial activity concentration is determined based on comprehensive calculation of the myocardial activity concentration of the three regions obtained by data sampling.